



Casgevy in India

The CDSCO cross-border QTC referral pathway — indicative 2026

RARE DISEASE · CRISPR GENE THERAPY SCD/TDT

The clinical situation

Casgevy (exagamglogene autotemcel) is a one-time infusion of CRISPR-Cas9-edited autologous haematopoietic stem cells for severe sickle cell disease and transfusion-dependent beta-thalassemia. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The editing disrupts a BCL11A regulatory region to reactivate foetal haemoglobin. Treatment involves mobilisation, apheresis, a multi-week manufacturing window, myeloablative conditioning, infusion, and extended inpatient engraftment recovery at an authorised Qualified Treatment Centre (QTC).

The pathway, 5 steps

- 1 Consultation & eligibility.** Haematologist confirms severe SCD or TDT diagnosis, crisis/transfusion history, organ-system baseline, and fitness for myeloablative conditioning.
- 2 QTC referral.** Reserve Meds coordinates cross-border referral to a Casgevy-qualified centre via our international care-coordination network.
- 3 CDSCO cross-border medical-referral dossier.** Your physician files the cross-border referral with rationale, QTC identification, and long-term follow-up plan.
- 4 Mobilisation, apheresis & manufacturing.** Conducted at the QTC; several-week manufacturing window; bridging transfusion support locally or at the QTC.
- 5 Conditioning, infusion & engraftment.** QTC inpatient stay 4–6+ weeks; handover to your Indian haematologist for long-term follow-up.

Indicative economics

Reference US list price: USD 2.0–2.3M one-time for the gene-therapy product; total cost of care at a US QTC typically runs substantially higher (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

12–24 weeks from intake to infusion, driven by the manufacturing window and QTC calendar. Inpatient stay 4–6+ weeks. Indicative — not guaranteed.

Reserve Meds's role

QTC referral. Coordination with authorised Casgevy centres through our clinical network. **Documentation.** Cross-border referral and CDSCO named-patient package. **Logistics.** Patient and caregiver travel, visa support, accommodation near the QTC, and post-infusion return-home planning. **Concierge case lead.** Named point of contact throughout the extended treatment journey. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist and the QTC team.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Casgevy × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/casgevy-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team